- Home
- FYBR vs CORT Comparison
FYBR vs CORT Comparison
Compare FYBR & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FYBR
- CORT
- Stock Information
- Founded
- FYBR 1935
- CORT 1998
- Country
- FYBR United States
- CORT United States
- Employees
- FYBR N/A
- CORT N/A
- Industry
- FYBR Telecommunications Equipment
- CORT Biotechnology: Pharmaceutical Preparations
- Sector
- FYBR Consumer Discretionary
- CORT Health Care
- Exchange
- FYBR Nasdaq
- CORT Nasdaq
- Market Cap
- FYBR 9.0B
- CORT 7.1B
- IPO Year
- FYBR N/A
- CORT N/A
- Fundamental
- Price
- FYBR $36.52
- CORT $71.38
- Analyst Decision
- FYBR Buy
- CORT Strong Buy
- Analyst Count
- FYBR 9
- CORT 4
- Target Price
- FYBR $35.33
- CORT $142.00
- AVG Volume (30 Days)
- FYBR 1.9M
- CORT 1.4M
- Earning Date
- FYBR 04-29-2025
- CORT 05-05-2025
- Dividend Yield
- FYBR N/A
- CORT N/A
- EPS Growth
- FYBR N/A
- CORT 8.36
- EPS
- FYBR N/A
- CORT 1.14
- Revenue
- FYBR $5,986,000,000.00
- CORT $685,446,000.00
- Revenue This Year
- FYBR $4.41
- CORT $36.81
- Revenue Next Year
- FYBR $2.92
- CORT $32.00
- P/E Ratio
- FYBR N/A
- CORT $62.48
- Revenue Growth
- FYBR 3.69
- CORT 30.93
- 52 Week Low
- FYBR $24.43
- CORT $25.35
- 52 Week High
- FYBR $39.21
- CORT $117.33
- Technical
- Relative Strength Index (RSI)
- FYBR 70.75
- CORT 52.32
- Support Level
- FYBR $36.15
- CORT $67.00
- Resistance Level
- FYBR $36.57
- CORT $75.41
- Average True Range (ATR)
- FYBR 0.13
- CORT 3.83
- MACD
- FYBR 0.03
- CORT -0.09
- Stochastic Oscillator
- FYBR 91.53
- CORT 66.78
About FYBR Frontier Communications Parent Inc.
Frontier Communications Parent Inc is a communications and technology provider offering broadband services. The company provides voice services, including data-based voice over Internet protocol (VoIP) and unified communications as a service (UCaaS), as well as long-distance and voice messaging services, to consumer and business customers in all its markets.
About CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.